Correlation between FDG uptake by PET/CT and the expressions of glucose transporter type 1 and hexokinase II in cervical cancer

International Journal of Gynecological Cancer

Volumn 22, Issue 4, 2012, Pages 654-658

  Tong, Seo Yun ^a   Lee, Jong Min ^a   Ki, Kyung Do ^a   Choi, Young Joon ^a   Seol, Hyun Joo ^a   Lee, Seon Kyung ^a   Huh, Chu Yeop ^a   Kim, Gou Young ^b   Lim, Sung Jig ^b  

^a Kyung Hee University College of Medicine   (South Korea)

^b Kyung Hee University Hospital   (South Korea)

Author keywords

Cervical cancer; Glucose transporter 1; Hexokinase II; Lymph node metastasis; PET CT

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GLUCOSE TRANSPORTER 1; HEXOKINASE; HEXOKINASE ISOENZYME; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ADENOSQUAMOUS CARCINOMA; ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FALSE POSITIVE RESULT; FEMALE; HUMAN; HUMAN TISSUE; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL CARCINOMA; TUMOR VOLUME; UTERINE CERVIX CANCER;

ADENOCARCINOMA; ADULT; AGED; CARCINOMA, ADENOSQUAMOUS; CARCINOMA, SQUAMOUS CELL; FALSE NEGATIVE REACTIONS; FALSE POSITIVE REACTIONS; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; GLUCOSE TRANSPORTER TYPE 1; HEXOKINASE; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPH NODES; LYMPHATIC METASTASIS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RADIOGRAPHIC IMAGE INTERPRETATION, COMPUTER-ASSISTED; RADIOPHARMACEUTICALS; UTERINE CERVICAL NEOPLASMS;

EID: 84863648278     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e31824864e6     Document Type: Article

References (30)

1. Girardi F, Pickel H, Winter R. Pelvic and parametrial lymph nodes in the quality control of the surgical treatment of cervical cancer. Gynecol Oncol. 1993;50:330-333.
2. Sakuragi N, Satoh C, Takeda N, et al. Incidence and distribution pattern of pelvic and paraaortic lymph node metastasis in patients with stages IB, IIA, and IIB cervical carcinoma treated with radical hysterectomy. Cancer. 1999;85:1547-1554.
3. Lee JM, Lee KB, Lee SK, et al. Pattern of lymph node metastasis and the optimal extent of pelvic lymphadenectomy in FIGO stage IB cervical cancer. J Obstet Gynaecol Res. 2007;33:288-293.
4. Magne N, Chargari C, Vicenzi L, et al. New trends in the evaluation and treatment of cervix cancer: the role of FDG-PET. Cancer Treat Rev. 2008;34:671-681.
5. Son H, Kositwattanarerk A, Hayes MP, et al. PET/CTevaluation of cervical cancer: spectrum of disease. Radiographics. 2010;30:1251-1268.
6. Lee DW, Kim YT, Kim JH, et al. Clinical significance of tumor volume and lymph node involvement assessed by MRI in stage IIB cervical cancer patients treated with concurrent chemoradiation therapy. J Gynecol Oncol. 2010;21:18-23.
7. Sugawara Y, Eisbruch A, Kosuda S, et al. Evaluation of FDG PET in patients with cervical cancer. J Nucl Med. 1999;40:1125-1131.
8. Choi HJ, Roh JW, Seo SS, et al. Comparison of the accuracy of magnetic resonance imaging and positron emission tomography/computed tomography in the presurgical detection of lymph node metastases in patients with uterine cervical carcinoma: a prospective study. Cancer. 2006;106:914-922.
9. Kim SK, Choi HJ, Park SY, et al. Additional value of MR/PET fusion compared with PET/CT in the detection of lymph node metastases in cervical cancer patients. Eur J Cancer. 2009;45:2103-2109.
10. Choi HJ, Ju W, Myung SK, et al. Diagnostic performance of computer tomography, magnetic resonance imaging, and positron emission tomography or positron emission tomography/computer tomography for detection of metastatic lymph nodes in patients with cervical cancer: meta-analysis. Cancer Sci. 2010;101:1471-1479.
11. Oriuchi N, Higuchi T, Ishikita T, et al. Present role and future prospects of positron emission tomography in clinical oncology. Cancer Sci. 2006;97:1291-1297.
12. Gambhir SS. Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer. 2002;2:683-693.
13. Grigsby PW. The contribution of new imaging techniques in staging cervical cancer. Gynecol Oncol. 2007;107(1 suppl 1):S10-S12.
14. Pauwels EK, Sturm EJ, Bombardieri E, et al. Positron emission tomography with [18F]fluorodeoxyglucose. Part I. Biochemical uptake mechanism and its implication for clinical studies. J Cancer Res Clin Oncol. 2000;126:549-559.
15. Gu J, Yamamoto H, Fukunaga H, et al. Correlation of GLUT-1 overexpression, tumor size, and depth of invasion with 18F-2-fluoro-2-deoxy-D- glucose uptake by positron emission tomography in colorectal cancer. Dig Dis Sci. 2006;51:2198-2205.
16. de Geus-Oei LF, van Krieken JH, Aliredjo RP, et al. Biological correlates of FDG uptake in non-small cell lung cancer. Lung Cancer. 2007;55:79-87.
17. Yen TC, See LC, Lai CH, et al. 18F-FDG uptake in squamous cell carcinoma of the cervix is correlated with glucose transporter 1 expression. J Nucl Med. 2004;45:22-29.
18. Kurokawa T, Yoshida Y, Kawahara K, et al. Expression of GLUT-1 glucose transfer, cellular proliferation activity and grade of tumor correlate with [F-18]-fluorodeoxyglucose uptake by positron emission tomography in epithelial tumors of the ovary. Int J Cancer. 2004;109:926-932.
19. Younes M, Lechago LV, Somoano JR, et al. Wide expression of the human erythrocyte glucose transporter Glut1 in human cancers. Cancer Res. 1996;56:1164-1167.
20. Mathupala SP, Rempel A, Pedersen PL. Aberrant glycolytic metabolism of cancer cells: a remarkable coordination of genetic, transcriptional, post-translational, and mutational events that lead to a critical role for type II hexokinase. J Bioenerg Biomembr. 1997;29:339-343.
21. Haberkorn U, Ziegler SI, Oberdorfer F, et al. FDG uptake, tumor proliferation and expression of glycolysis associated genes in animal tumor models. Nucl Med Biol. 1994;21:827-834.
22. Chung HH, Kang KW, Cho JY, et al. Role of magnetic resonance imaging and positron emission tomography/computed tomography in preoperative lymph node detection of uterine cervical cancer. Am J Obstet Gynecol. 2010;203:156 e151-156 e155.
23. Subhas N, Patel PV, Pannu HK, et al. Imaging of pelvic malignancies with in-line FDG PET-CT: case examples and common pitfalls of FDG PET. Radiographics. 2005;25:1031-1043.
24. Loft A, Berthelsen AK, Roed H, et al. The diagnostic value of PET/CT scanning in patients with cervical cancer: a prospective study. Gynecol Oncol. 2007;106:29-34.
25. Mamede M, Higashi T, Kitaichi M, et al. [18F]FDG uptake and PCNA, Glut-1, and Hexokinase-II expressions in cancers and inflammatory lesions of the lung. Neoplasia. 2005;7:369-379.
26. Paudyal B, Oriuchi N, Paudyal P, et al. Expression of glucose transporters and hexokinase II in cholangiocellular carcinoma compared using [18F]-2-fluro-2-deoxy-D-glucose positron emission tomography. Cancer Sci. 2008;99:260-266.
27. Shim HK, Lee WW, Park SY, et al. Expressions of glucose transporter types 1 and 3 and hexokinase-II in diffuse large B-cell lymphoma and other B-cell non-Hodgkin's lymphomas. Nucl Med Biol. 2009;36:191-197.
28. Higashi T, Tamaki N, Honda T, et al. Expression of glucose transporters in human pancreatic tumors compared with increased FDG accumulation in PET study. J Nucl Med. 1997;38:1337-1344.
29. Park W, Park YJ, Huh SJ, et al. The usefulness of MRI and PET imaging for the detection of parametrial involvement and lymph node metastasis in patients with cervical cancer. Jpn J Clin Oncol. 2005;35:260-264.
30. Wright JD, Dehdashti F, Herzog TJ, et al. Preoperative lymph node staging of early-stage cervical carcinoma by [18F]-fluoro-2-deoxy-D-glucose-positron emission tomography. Cancer. 2005;104:2484-2491.